Douglas L. Leslie

TL;DR: The economic impact of delirium is substantial, rivaling the health care costs of falls and diabetes mellitus, and the need for increased efforts to mitigate this clinically significant and costly disorder is highlighted.

TL;DR: In this large group of patients with schizophrenia, receipt of a prescription for atypical neuroleptics was significantly associated with diabetes mellitus, and the prevalence of diabetes was significantly increased for patients who received clozapine, olanzapines, and quetiapins, but not risperidone.

TL;DR: It is very unlikely that $50,000 per Quality-Adjusted Life-Year (QALY) is consistent with societal preferences in the United States.

TL;DR: Patients with CLBP are characterized by greater comorbidity and economic burdens compared with those without CLBP, and this economic burden can be attributed to greater prescribing of pain-related medications and increased health resource utilization.

TL;DR: Overall employment of persons with schizophrenia seems to be impeded by clinical problems, including symptoms of schizophrenia and poorer neurocognitive and intrapsychic functioning, however, participation in competitive employment may be specifically impeding by the potentially adverse incentives of disability payments and by race and may be promoted by the availability of rehabilitation services.